Forecast

There is no analyst data available for this company.

News Go to news feed

Hönle increases profit in Q3 2026 despite only slight revenue growth

Hönle reports a Q3 2026 revenue increase of 4.9% to €23.7m and an EBITDA of €1.7m versus €0.5m a year earlier, lifting the margin to 7.3%. In the nine-month period revenue remained stable at €69m, while EBITDA rose 26% to €4.5m. Improved cost discipline, a more favorable product mix and lower material costs contributed to the margin improvement, while the curing segment remains under pressure. Management confirmed the full-year guidance (revenue €92–95m, EBITDA €5–6m) and expects curing to grow again in fiscal 2026/2027. » More on de.investing.com
Dr Hönle executive expands stake and buys 56,680 shares

On 9 December 2025 Dr. Richter Vermögens- und Beteiligungsverwaltung GmbH (board member) acquired 56,680 Dr Hönle shares at €6.80 each; the trade was reported on 10 December 2025. The announcement temporarily pushed the price higher in FSE trading; the stock closed at €6.82 (+2.10%). The executive had previously bought 27,008 shares at €16.66 each on 22 February 2024. » More on finanzen.net
Dr Hönle expects significant improvement in quarterly results

Dr Hönle will present figures for the past quarter on August 7, 2025. Analysts forecast earnings per share of 0.050 EUR, compared to a loss in the same quarter last year, and expect revenue to rise to 26.3 million EUR. A significant improvement in results is also anticipated for the current fiscal year. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Dr. Hönle has already paid 0,20€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Dr. Hönle had revenue of 23.71m€ and net profit of −224.00k€

(EUR)	Jun 2026	YoY
Revenue	+23.71m	4,71%
Gross profit	+3.40m	76,09%
Net profit	−224.00k	75,30%
EBITDA	+1.98m	1.324,07%

Fundamentals

Metric	Value
Market capitalization	+44.09m€
Number of shares	5.51m
52-week high/low	+23,60€ - +7,92€
Dividends	No
Beta	1,49
P/E ratio	−16,65
PEG ratio	−0,24
P/B ratio	+0,63
P/S ratio	+0,52

Company profile

Die Dr. Hönle AG liefert industrielle UV-Technologien und -Anlagen in Deutschland und international. Das Unternehmen ist in drei Segmenten tätig: Klebstoffe, Geräte & Anlagen sowie Glas & Strahler. Das Segment Klebstoffe bietet industrielle Klebstoffe für Anwendungen wie Unterhaltungselektronik, Medizintechnik, Optik und Optoelektronik, Automotive und Glasverarbeitung. Das Segment Geräte & Systeme befasst sich mit der Trocknung von Farben und Beschichtungen, der Aushärtung von Klebstoffen und Kunststoffen, der Desinfektion von Oberflächen und der Sonnensimulation. Das Segment Glas & Lampen bietet Quarzglasrohre und -stäbe für die Lampen-, Automobil-, Halbleiter- und Faserkabelindustrie sowie Lampen für die Wasserentkeimung und die Trocknung von Beschichtungen und Klebstoffen an. Das Unternehmen wurde 1976 gegründet und hat seinen Hauptsitz in München, Deutschland.

Name	Dr. Hönle
CEO	Franz Richter
Headquarters	Gilching, bv Germany
Website	hoenle.de
Sector	Information Technology
Industry	Technology Hardware, Storage & Peripherals
IPO	01/24/2001
Employees	567